BioStem’s Diabetic Foot Ulcer Trial Reaches Completion: What Investors Should Watch Next

BioStem Technologies (BSEM) announced an update on their ongoing clinical study.

BioStem Technologies (BSEM) has reported an update on its prospective, multicenter trial titled “A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC.” The study aims to see whether adding BioREtain Amnion Chorion (BR-AC) to standard wound care improves healing in stubborn diabetic foot ulcers compared with standard care alone. For investors, this matters because diabetic foot ulcers are a costly, high-need segment of the chronic wound market, and any credible data showing faster or more complete healing could support broader clinical uptake and reimbursement for BioStem’s products.

The trial is testing BR-AC, a placental membrane graft produced by BioStem using its BioREtain process. BR-AC is applied directly to the wound along with standard care, which includes cleaning, debridement, dressings, and devices that reduce pressure on the foot. The goal is to promote better wound closure and reduce complications. The control group receives only standard care, allowing a clear comparison of how much benefit BR-AC may add.

The study is an interventional, randomized, controlled trial with two parallel groups: one gets BR-AC plus standard care, and the other receives standard care only. Patients are assigned randomly to each arm to reduce bias. Outcome assessment uses single masking: an independent reviewer, who does not know which treatment the patient received, reviews wound images to confirm when closure occurs. The primary purpose is treatment, meaning the main question is whether BR-AC improves healing in real-world diabetic ulcer patients versus current best practice.

The study was first submitted in July 2024, marking the formal start of regulatory and site setup. The overall status is now listed as completed, with the latest update submitted on January 21, 2026. That recent update signals that follow-up and data collection have likely finished and the sponsor is moving toward full analysis and, potentially, public disclosure of top-line results. No primary completion or results posting dates are yet recorded in the registry, which suggests that investors should watch for the first data release over the coming months.

From a market perspective, confirmation that this pivotal trial is completed removes execution risk around enrollment and follow-up, which is often a concern for small-cap biotech and medtech names. If forthcoming data show a clear advantage for BR-AC in closing diabetic foot ulcers, BioStem could see stronger adoption of its BioREtain platform, improved payer interest, and a higher valuation multiple in line with peers in advanced wound care. The competitive set includes other advanced biologic dressings and skin substitutes; any signal of superior healing, fewer amputations, or cost savings would be a key differentiator. On the other hand, inconclusive or negative results would likely pressure the stock and limit near-term commercial expansion, so this update mainly heightens anticipation ahead of results rather than changing the fundamental outlook today. The trial is now completed and recently updated, with further details and future results to be made available on the ClinicalTrials.gov portal.